

“I’m afraid, but I’m trying to get on with my life so my family doesn’t worry too much. I might lose my hair and even my breasts... I don’t know what the future will be, but I’m going to do whatever it takes to beat this disease.”

BREAST CANCER: the two words a woman may fear most. But all breast cancers are not alike. Current research confirms that breast cancer is not a single disease, but one that has different subtypes. One of these subtypes is **triple negative breast cancer**, or TNBC. TNBC, which is seen more often in African American women and younger women, can be aggressive, with a higher likelihood of recurrence. TNBC accounts for only 10-15% of all breast cancers, but may be responsible for as many as 10,000 deaths every year in the US alone.

Officers

Triple Negative Breast Cancer Foundation

Honorary Founder

Nancy Block-Zenna

Acting Executive Director

Hayley Dinerman

Board of Trustees

Allison Axenrod
Malaak Compton-Rock
Kurt Nygaard, Chair
Jennifer K. Sweetwood
Eric P. Winer, MD

Advisory Board

Lisa A. Carey, MD
Associate Professor of Medical Oncology and
Medical Director, UNC Breast Center
University of North Carolina - Lineberger Comprehensive
Cancer Center

Susan M. Domchek, MD
Basser Professor of Oncology at the University of Pennsylvania
Director of the MacDonald Cancer Risk Evaluation Program
at the Abramson Cancer Center
Executive Director of the Basser Research Center

Lisa A. Newman, MD, MPH FACS
Director, Breast Cancer Center
Professor of Surgery
University of Michigan Comprehensive Cancer Center

George W. Sledge, Jr. MD
Chief of Oncology, Department of Medicine
Stanford University Medical Center


Eric P. Winer, MD
Professor of Medicine
Harvard Medical School
Chief, Division of Women's Cancers
Dana-Farber Cancer Institute



Searching for a Cure

The most common breast cancer treatments usually target three receptors found in tumors: estrogen, progesterone, and HER2-neu. **“Triple negative”** means that the breast cancer is estrogen receptor-negative, progesterone receptor-negative, and HER2-negative. Although triple negative tumors may be highly responsive to chemotherapy, they may also be more difficult to treat because there is no targeted treatment.

One woman who lost her two-year battle with TNBC was Nancy Block-Zenna, a young mother diagnosed at age 35. In her honor, some of Nancy's friends created the **Triple Negative Breast Cancer Foundation**. The Foundation's mission is to be a credible source for triple negative breast cancer information, a catalyst for science and patient advocacy groups, and a caring community with meaningful services for patients and their families.



THE FOUNDATION'S GOALS:

- **Ignite interest** in the study of TNBC among researchers, scientists, physicians, and educators
- **Support health professionals** seeking to identify the causes of TNBC and discover new and effective treatment options
- **Support the TNBC community** through our website, hotline, and educational resources
- **Increase public awareness** of this breast cancer subtype

Visit our website at: www.tnbcfoundation.org to make a donation and to explore the range of support services and educational resources available. We encourage you to get involved to help conquer this disease. You may also contact us at:

TNBC Foundation
PO Box 204
Norwood, NJ 07648
(646) 942-0242
(877) 880-TNBC (8622)
info@tnbcfoundation.org
www.tnbcfoundation.org

The Triple Negative Breast Cancer Foundation is dedicated to supporting the TNBC community, raising public awareness of the disease and supporting TNBC specific research.

The Triple Negative Breast Cancer Foundation, Inc. is a New Jersey nonprofit corporation that is exempt from Federal income tax, under section 501(c)(3) of the Internal Revenue Code. Contributions are tax deductible for federal income tax purposes to the full extent of the law.

